Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Electron Transport Chain: Complex I and II

Electron Transport Chain: Complex I and II

The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...

Mitochondrial Precursor Proteins

Mitochondrial Precursor Proteins

Mitochondrial precursors are partially unfolded or loosely folded polypeptide chains. Newly synthesized precursors are inhibited from spontaneously folding into their native conformation by the cytosolic chaperones, heat shock proteins 70 (Hsp70), and mitochondrial import stimulation factors (MSFs). Precursors bound to MSFs are guided to the TOM70-TOM37 receptors, while precursors bound to Hsp70 chaperones are targetted to TOM20-TOM22 receptor complexes.
Most of the mitochondrial...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Synthesis of Spiroindenes via Palladium Catalysis Using Oxabicycles as Acetylene Surrogates.

Organic letters·2025

Same author

Impact of Winter Season on Inpatient Outcomes and Trends in Cardiac Arrest Hospitalizations: A Nationwide Analysis.

Cureus·2025

Same author

Heart Failure Part 3: Diuretic Management in Older People.

The Senior care pharmacist·2024

Same author

Addressing the Complex Needs of Customers Who Contact the Veterans Crisis Line.

Crisis·2024

Same author

Outcomes of Ultrafiltration in community-based hospitals.

Current problems in cardiology·2024

Same author

Implementing and evaluating a veterans crisis line quality improvement initiative: The safety planning pilot program.

Psychological services·2024

Search research articles

Related Experiment Video

Updated: Oct 6, 2025

Experimental Protocol for Detecting Mitochondrial Function in Hepatocytes Exposed to Organochlorine Pesticides

Experimental Protocol for Detecting Mitochondrial Function in Hepatocytes Exposed to Organochlorine Pesticides

Published on: September 16, 2020

Targeting mitochondrial dysfunction with elamipretide.

Chukwuemeka Obi¹, Alexander T Smith², Gregory J Hughes^3,4

¹Division of Cardiology, Medical University of South Carolina, 30 Courtenay Drive, Charleston, SC, 29425, USA.

Heart Failure Reviews

|January 17, 2022

Summary

New research explores elamipretide, a novel drug targeting mitochondria, to treat heart failure. Early trials show promise in improving cardiac function and preventing adverse remodeling, offering hope for new heart failure therapies.

Keywords:

Cardiolipin Elamipretide Heart failure Mitochondrial dysfunction

More Related Videos

Author Spotlight: Decoding Mitochondrial Aging

Author Spotlight: Decoding Mitochondrial Aging

Published on: June 30, 2023

Quantitative Analysis of Mitochondria-Associated Endoplasmic Reticulum Membrane (MAM) Stabilization in a Neural Model of Alzheimer's Disease (AD)

Quantitative Analysis of Mitochondria-Associated Endoplasmic Reticulum Membrane (MAM) Stabilization in a Neural Model of Alzheimer's Disease (AD)

Published on: January 10, 2025

Related Experiment Videos

Last Updated: Oct 6, 2025

Experimental Protocol for Detecting Mitochondrial Function in Hepatocytes Exposed to Organochlorine Pesticides

Experimental Protocol for Detecting Mitochondrial Function in Hepatocytes Exposed to Organochlorine Pesticides

Published on: September 16, 2020

Author Spotlight: Decoding Mitochondrial Aging

Author Spotlight: Decoding Mitochondrial Aging

Published on: June 30, 2023

Quantitative Analysis of Mitochondria-Associated Endoplasmic Reticulum Membrane (MAM) Stabilization in a Neural Model of Alzheimer's Disease (AD)

Quantitative Analysis of Mitochondria-Associated Endoplasmic Reticulum Membrane (MAM) Stabilization in a Neural Model of Alzheimer's Disease (AD)

Published on: January 10, 2025

Area of Science:

Biochemistry
Cardiology
Pharmacology

Background:

Current heart failure therapies offer temporary benefits but do not halt disease progression.
Understanding of heart failure progression remains incomplete, necessitating novel therapeutic strategies.
Mitochondria play a critical role in cellular energy production and programmed cell death, making them a key target for intervention.

Purpose of the Study:

To investigate the potential of elamipretide as a novel therapeutic agent for heart failure.
To evaluate elamipretide's mechanism of action in maintaining cellular bioenergetics and preventing oxidative stress.
To assess the safety and efficacy of elamipretide in preclinical models and early-phase clinical trials.

Main Methods:

Literature review of current heart failure research and novel therapeutic targets.
Preclinical studies in dog models of heart failure with reduced ejection fraction and rat models of cardiac remodeling.
Early-phase clinical trials to assess safety, tolerability, and hemodynamic effects of elamipretide.

Main Results:

Elamipretide demonstrated increased left ventricular ejection fraction in canine heart failure models.
Elamipretide prevented left ventricular remodeling in rat models.
Early clinical trials indicated no severe adverse events and showed promising cardiac hemodynamic improvements at higher doses.

Conclusions:

Elamipretide targets mitochondria to maintain cellular function and prevent damage in heart failure.
Preclinical and early clinical data suggest elamipretide is a potential new therapy for heart failure.
Further long-term studies are required to confirm the safety and efficacy of elamipretide.